A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Public ClinicalTrials.gov record NCT02158858. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 1 Part: This was an open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients who had previously been treated for Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms. Phase 2 Part: This was an open-label study of pelabresib (CPI-0610), administered with and without Ruxolitinib, in patients diagnosed with Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia). Pelabresib (CPI-0610) was a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Study identification
- NCT ID
- NCT02158858
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 336 participants
Conditions and interventions
Conditions
- Myelofibrosis
- Leukemia, Myelocytic, Acute
- Myelodysplastic/Myeloproliferative Neoplasm
- Myelodysplastic Syndrome (MDS)
- Preleukemia
- Primary Myelofibrosis
- Myeloproliferative Disorders
- Bone Marrow Disease
- Hematological Disease
- Precancerous Conditions
- Neoplasms
- Leukemia
- Neoplasms by Histologic Type
- Essential Thrombocytosis
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 16, 2014 (Actual)
- Primary completion
- Jan 9, 2025 (Actual)
- Completion
- Jan 9, 2025 (Actual)
- Last update posted
- Jun 4, 2026
2014 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| Northwestern University - Lurie Comprehensive Cancer Center | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | — |
| University of Michigan Medical Center | Ann Arbor | Michigan | 48109 | — |
| Washington University School of Medicne Neuromuscular Division Department of Neurology Research | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| ICAHN School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Weill Medical College and New York Presbyterian Hospital | New York | New York | 10065 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Froedtert & Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02158858, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02158858 live on ClinicalTrials.gov.